Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential.
Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential.
复制标题
DOI：
10.1155/2022/2104880
复制
发表时间：
2022
影响因子：
3.1
通讯作者：
Moebius, Hans J.
中科院分区：
文献类型：
--
作者：
Olichney, John;Xia, Jiangyi;Church, Kevin J.;Moebius, Hans J.
神经退行性疾病，如阿尔茨海默病（AD），及其相关的认知功能恶化是残疾的常见原因。神经退行性疾病的病理学发展缓慢，需要早期诊断和监测长期治疗。缺乏有效的治疗方法，加上我们老龄化人口中早期诊断率的提高，迫切需要开发新的药物，以及需要可靠的生物标志物用于治疗反应。这些问题与AD尤其相关，其中临床试验药物失败率非常高。经常使用的生物标志物评估程序，如正电子发射断层扫描或磷酸化tau和淀粉样蛋白β的脑脊液测量，是侵入性的和昂贵的，并且不是普遍可用或可获得的。本文综述了事件相关电位（ERP）P300方法作为预测神经认知障碍药物临床开发中促认知潜力的替代生物标志物的功能。通过标准化脑电图（EEG）的应用，可以可靠地测量ERP P300。P300波形客观地测量大规模神经元网络功能和工作记忆过程。在认知障碍的文献中，ERP P300潜伏期增加，支持ERP P300作为许多神经系统和神经精神疾病（包括AD）的生物标志物的潜在效用。具体而言，本文提供的证据支持ERP P300潜伏期作为检测AD痴呆患者从轻度到中度认知障碍进展和药物治疗后认知变化的定量、无偏倚指标。
Neurodegenerative diseases, such as Alzheimer's disease (AD), and their associated deterioration of cognitive function are common causes of disability. The slowly developing pathology of neurodegenerative diseases necessitates early diagnosis and monitored long-term treatment. Lack of effective therapies coupled with an improved rate of early diagnosis in our aging population have created an urgent need for the development of novel drugs, as well as the need for reliable biomarkers for treatment response. These issues are especially relevant for AD, in which the rate of clinical trial drug failures has been very high. Frequently used biomarker evaluation procedures, such as positron emission tomography or cerebrospinal fluid measurements of phospho-tau and amyloid beta, are invasive and costly, and not universally available or accessible. This review considers the functionality of the event-related potential (ERP) P300 methodology as a surrogate biomarker for predicting the procognitive potential of drugs in clinical development for neurocognitive disorders. Through the application of standardized electroencephalography (EEG) described here, ERP P300 can be reliably measured. The P300 waveform objectively measures large-scale neuronal network functioning and working memory processes. Increased ERP P300 latency has been reported throughout the literature in disorders of cognition, supporting the potential utility of ERP P300 as a biomarker in many neurological and neuropsychiatric disorders, including AD. Specifically, evidence presented here supports ERP P300 latency as a quantitative, unbiased measure for detecting changes in cognition in patients with AD dementia through the progression from mild to moderate cognitive impairment and after drug treatment.
登录
查看更多内容
影响因子：
4.7
作者：
Golob, EJ;Starr, A
通讯作者：
Starr, A
DOI：
10.1016/j.dadm.2015.08.004
发表时间：
2015-12-01
期刊：
Alzheimer's & dementia (Amsterdam, Netherlands)
影响因子：
--
作者：
Cecchi, Marco;Moore, Dennis K;Fadem, Kalford C
通讯作者：
Fadem, Kalford C
影响因子：
9.9
作者：
Golob, E. J.;Ringman, J. M.;Starr, A.
通讯作者：
Starr, A.
DOI：
10.1111/cts.12491
发表时间：
2018-03
期刊：
Clinical and translational science
影响因子：
--
作者：
Cummings J
通讯作者：
Cummings J
影响因子：
3.4
作者：
de Aquino CH
通讯作者：
de Aquino CH